Evaluation of a new heterogeneous immunoassay for the whole-blood determination of cyclosporin on the dade Behring dimension RXL clinical chemistry analyzer

被引:0
作者
Morand, K [1 ]
Huet, E [1 ]
Blanchet, B [1 ]
Astier, A [1 ]
Hulin, A [1 ]
机构
[1] CHU Henri Mondor, Lab Pharmacol & Toxicol, F-94010 Creteil, France
关键词
heterogeneous immunoassay; cyclosporin monitoring; immunosuppressive drug; RXL HM Dimension (R);
D O I
暂无
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
We propose an evaluation of a new heterogenous immunoassay of cyclosporin on RXL HM Dimension((R)) (Dade Behring) for therapeutic cyclosporin monitoring in whole-blood patients transplant. The pretreatment step is performed automatically into the apparatus while it is a manual step with EMIT. Linearity, intra- and inter-day precision, limit of quantification, precision and accuracy of dilution steps and stability into the equipment were studied. We realized the comparison between ACMIA and EMIT methods on whole-blood patients transplant recipients. Heterogeneous immunoassay showed a good linearity between 0 and 500 ng/mL, intra- and inter-day precision with coefficient of variation inferior to 7.2%. We observed reproductible and accurate dilutions of high concentrations (500 to 2,000 ng/mL). The correlation with EMIT technique was correct for different type of transplant (n = 55).
引用
收藏
页码:713 / 718
页数:6
相关论文
共 11 条
[1]   Methods for clinical monitoring of cyclosporin in transplant patients [J].
Dumont, RJ ;
Ensom, MHH .
CLINICAL PHARMACOKINETICS, 2000, 38 (05) :427-447
[2]   CYCLOSPORINE MONITORING IN RENAL-TRANSPLANTATION - AREA UNDER THE CURVE MONITORING IS SUPERIOR TO TROUGH-LEVEL MONITORING [J].
GREVEL, J ;
WELSH, MS ;
KAHAN, BD .
THERAPEUTIC DRUG MONITORING, 1989, 11 (03) :246-248
[3]   AREA UNDER THE CURVE MONITORING OF CYCLOSPORINE THERAPY - THE EARLY POSTTRANSPLANT PERIOD [J].
GREVEL, J ;
KAHAN, BD .
THERAPEUTIC DRUG MONITORING, 1991, 13 (02) :89-95
[4]   Whole blood cyclosporin monitoring in liver and heart transplant patients: Evaluation of the specificity of a fluorescence polarization immunoassay and an enzyme-multiplied immunoassay technique [J].
Gulbis, B ;
VanderHeijden, J ;
vanAs, H ;
Thiry, P .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 1997, 15 (07) :957-963
[5]  
Hamwi A, 1999, AM J CLIN PATHOL, V112, P358
[6]   Cyclosporine metabolism in patients after kidney, bone marrow, heart-lung, and liver transplantation in the early and late posttransplant periods [J].
Hamwi, A ;
Salomon, A ;
Steinbrugger, R ;
Fritzer-Szekeres, M ;
Jäger, W ;
Szekeres, T .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2000, 114 (04) :536-543
[7]  
Holt DW, 2000, CLIN CHEM, V46, P872
[8]   CHALLENGES IN CYCLOSPORINE THERAPY - THE ROLE OF THERAPEUTIC MONITORING BY AREA-UNDER-THE-CURVE MONITORING [J].
KAHAN, BD ;
WELSH, M ;
RUTZKY, LP .
THERAPEUTIC DRUG MONITORING, 1995, 17 (06) :621-624
[9]  
Terrell AR, 2002, CLIN CHEM, V48, P1059
[10]  
VASSAULT A, 1997, SPECTRA BIOL, V16, P43